| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Xiang Yang Zhang, Dong Feng Zhou, Yu Cun Shen, Pei Yan Zhang, Wu Fang Zhang, Jun Liang, Da Chun Chen, Mei Hong Xiu, Therese A Kosten, Thomas R Koste. Effects of risperidone and haloperidol on superoxide dismutase and nitric oxide in schizophrenia. Neuropharmacology. vol 62. issue 5-6. 2012-07-23. PMID:22227558. |
effects of risperidone and haloperidol on superoxide dismutase and nitric oxide in schizophrenia. |
2012-07-23 |
2023-08-12 |
Not clear |
| Xiang Yang Zhang, Dong Feng Zhou, Yu Cun Shen, Pei Yan Zhang, Wu Fang Zhang, Jun Liang, Da Chun Chen, Mei Hong Xiu, Therese A Kosten, Thomas R Koste. Effects of risperidone and haloperidol on superoxide dismutase and nitric oxide in schizophrenia. Neuropharmacology. vol 62. issue 5-6. 2012-07-23. PMID:22227558. |
seventy-eight inpatients with chronic schizophrenia were randomly assigned to 12 weeks of treatment with 6 mg/day of risperidone or 20 mg/day of haloperidol using a double-blind design. |
2012-07-23 |
2023-08-12 |
Not clear |
| Xiang Yang Zhang, Dong Feng Zhou, Yu Cun Shen, Pei Yan Zhang, Wu Fang Zhang, Jun Liang, Da Chun Chen, Mei Hong Xiu, Therese A Kosten, Thomas R Koste. Effects of risperidone and haloperidol on superoxide dismutase and nitric oxide in schizophrenia. Neuropharmacology. vol 62. issue 5-6. 2012-07-23. PMID:22227558. |
both risperidone and haloperidol equivalently reduced the elevated blood sod levels in schizophrenia, but neither medication reduced the elevated plasma no levels in schizophrenia. |
2012-07-23 |
2023-08-12 |
Not clear |
| Renan P Souza, Arun K Tiwari, Nabilah I Chowdhury, Rolando B Ceddia, Jeffrey A Lieberman, Herbert Y Meltzer, James L Kennedy, Daniel J Mülle. Association study between variants of AMP-activated protein kinase catalytic and regulatory subunit genes with antipsychotic-induced weight gain. Journal of psychiatric research. vol 46. issue 4. 2012-07-20. PMID:22305490. |
to accomplish this, ten polymorphisms in 208 schizophrenia or schizoaffective disorder patients treated with clozapine, haloperidol, risperidone or olanzapine for up to 14 weeks were analyzed. |
2012-07-20 |
2023-08-12 |
Not clear |
| Rosario de Arce Cordón, Evelin Eding, Joao Marques-Teixeira, Vihra Milanova, Elmars Rancans, Andreas Schreine. Descriptive analyses of the aripiprazole arm in the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European archives of psychiatry and clinical neuroscience. vol 262. issue 2. 2012-07-16. PMID:21809168. |
clinically stable adults with schizophrenia or schizoaffective disorder previously treated with oral risperidone, olanzapine, or an oral conventional antipsychotic were randomized to rlai or aripiprazole. |
2012-07-16 |
2023-08-12 |
Not clear |
| J-J Chen, H-Y Chan, C-H Chen, S S-F Gau, H-G Hw. Risperidone and olanzapine versus another first generation antipsychotic in patients with schizophrenia inadequately responsive to first generation antipsychotics. Pharmacopsychiatry. vol 45. issue 2. 2012-07-16. PMID:22086749. |
risperidone and olanzapine versus another first generation antipsychotic in patients with schizophrenia inadequately responsive to first generation antipsychotics. |
2012-07-16 |
2023-08-12 |
Not clear |
| Martien Wampers, Linda Hanssens, Ruud van Winkel, Adrian Heald, Julien Collette, Joseph Peuskens, Jean Yves Reginster, Andre Scheen, Marc De Her. Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: results from a 3-month prospective open-label study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 22. issue 1. 2012-07-11. PMID:21511441. |
113 patients with schizophrenia (65.5% males, 32.3years old) who were free of antipsychotic medication were enrolled in this open-label prospective single-center study and received either risperidone (n=54) or olanzapine (n=59). |
2012-07-11 |
2023-08-12 |
Not clear |
| Mohammad Arbabi, Mohaddeseh Bagheri, Farzin Rezaei, Seyyed-Ali Ahmadi-Abhari, Mina Tabrizi, Farahnaz Khalighi-Sigaroudi, Shahin Akhondzade. A placebo-controlled study of the modafinil added to risperidone in chronic schizophrenia. Psychopharmacology. vol 220. issue 3. 2012-07-11. PMID:21947320. |
a placebo-controlled study of the modafinil added to risperidone in chronic schizophrenia. |
2012-07-11 |
2023-08-12 |
Not clear |
| Takefumi Suzuki, Gary Remington, Hiroyuki Uchida, Tarek K Rajji, Ariel Graff-Guerrero, David C Mam. Management of schizophrenia in late life with antipsychotic medications: a qualitative review. Drugs & aging. vol 28. issue 12. 2012-07-03. PMID:22117095. |
treatment of non-resistant, late-life schizophrenia with olanzapine and risperidone appears to be supported by the available evidence. |
2012-07-03 |
2023-08-12 |
Not clear |
| T A P Lett, T J M Wallace, N I Chowdhury, A K Tiwari, J L Kennedy, D J Mülle. Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Molecular psychiatry. vol 17. issue 3. 2012-06-29. PMID:21894153. |
second-generation antipsychotics (sgas), such as risperidone, clozapine and olanzapine, are the most common drug treatments for schizophrenia. |
2012-06-29 |
2023-08-12 |
Not clear |
| Bonnie A Fijal, Virginia L Stauffer, Bruce J Kinon, Robert R Conley, Vicki Poole Hoffmann, Michael M Witte, Fangyi Zhao, John P Housto. Analysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidone. The Journal of clinical psychiatry. vol 73. issue 3. 2012-06-28. PMID:21813073. |
analysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidone. |
2012-06-28 |
2023-08-12 |
Not clear |
| Fernanda Rosa, Andreas Schreiner, Pierre Thomas, Tarek Sheri. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable. Clinical drug investigation. vol 32. issue 4. 2012-06-28. PMID:22339430. |
switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable. |
2012-06-28 |
2023-08-12 |
Not clear |
| W Mahatthanatrakul, S Sriwiriyajan, W Ridtitid, J Boonleang, M Wongnawa, N Rujimamahasan, W Pipatrattanasere. Effect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers. Journal of clinical pharmacy and therapeutics. vol 37. issue 2. 2012-06-25. PMID:21518375. |
risperidone is an atypical antipsychotic agent used for the treatment of schizophrenia. |
2012-06-25 |
2023-08-12 |
human |
| Lamiae Grimaldi-Bensouda, Frederic Rouillon, Bernard Astruc, Michel Rossignol, Jacques Benichou, Bruno Falissard, Frederic Limosin, Beatrice Beaufils, Guillaume Vaiva, Helene Verdoux, Yola Moride, Alban Fabre, Florence Thibaut, Lucien Abenhai. Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS). Schizophrenia research. vol 134. issue 2-3. 2012-06-04. PMID:22130111. |
does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? |
2012-06-04 |
2023-08-12 |
Not clear |
| Maosheng Fang, Honghui Chen, Le-Hua Li, Renrong Wu, Yi Li, Lianzhong Liu, Meng Ye, Jizhong Huang, Suoyu Zhu, Gang Wang, Qinge Zhang, Hongbo Zheng, Lulu Zhang, Bo Wang, Jianchu Zhou, Jing-Ping Zha. Comparison of risperidone oral solution and intramuscular haloperidol with the latter shifting to oral therapy for the treatment of acute agitation in patients with schizophrenia. International clinical psychopharmacology. vol 27. issue 2. 2012-06-04. PMID:22233697. |
comparison of risperidone oral solution and intramuscular haloperidol with the latter shifting to oral therapy for the treatment of acute agitation in patients with schizophrenia. |
2012-06-04 |
2023-08-12 |
Not clear |
| Shifu Xiao, Haibo Xue, Guanjun Li, Chengmei Yuan, Xia Li, Chao Chen, Helen Zong Ying Wu, Philip Mitchell, Mingyuan Zhan. Therapeutic effects of cerebrolysin added to risperidone in patients with schizophrenia dominated by negative symptoms. The Australian and New Zealand journal of psychiatry. vol 46. issue 2. 2012-06-01. PMID:22311531. |
therapeutic effects of cerebrolysin added to risperidone in patients with schizophrenia dominated by negative symptoms. |
2012-06-01 |
2023-08-12 |
Not clear |
| Shifu Xiao, Haibo Xue, Guanjun Li, Chengmei Yuan, Xia Li, Chao Chen, Helen Zong Ying Wu, Philip Mitchell, Mingyuan Zhan. Therapeutic effects of cerebrolysin added to risperidone in patients with schizophrenia dominated by negative symptoms. The Australian and New Zealand journal of psychiatry. vol 46. issue 2. 2012-06-01. PMID:22311531. |
this study evaluated the efficacy and safety of cerebrolysin added to risperidone in patients with schizophrenia dominated by negative symptoms. |
2012-06-01 |
2023-08-12 |
Not clear |
| Wenting Shi, Jinglun Du, Yuhua Qi, Gaofeng Liang, Tianyu Wang, Shuchun Li, Shiping Xie, Basit Zeshan, Zhongdang Xia. Aberrant expression of serum miRNAs in schizophrenia. Journal of psychiatric research. vol 46. issue 2. 2012-05-25. PMID:22094284. |
in addition, we also found that the risperidone improved the serum mir-346 level of schizophrenia significantly, and therefore may not be an effective drug in regulating serum mir-346 level of schizophrenia. |
2012-05-25 |
2023-08-12 |
Not clear |
| Junzo Watanabe, Yutaro Suzuki, Naoki Fukui, Shin Ono, Takuro Sugai, Nobuto Tsuneyama, Toshiyuki Somey. Increased risk of antipsychotic-related QT prolongation during nighttime: a 24-hour holter electrocardiogram recording study. Journal of clinical psychopharmacology. vol 32. issue 1. 2012-05-23. PMID:22198445. |
sixty-six patients with a diagnosis of schizophrenia that were treated with risperidone or olanzapine and 40 healthy volunteers were enrolled. |
2012-05-23 |
2023-08-12 |
human |
| Christopher Reist, Joseph C Wu, Ylva Lilja, Jogeshwar Mukherjee, Dimitrios Gripeos, Cristian Constantinescu, Maria Augusta Raggi, Laura Mercolini, Vural Ozdemi. Ketoconazole-associated preferential increase in dopamine D2 receptor occupancy in striatum compared to pituitary in vivo: role for drug transporters? Journal of clinical psychopharmacology. vol 32. issue 1. 2012-05-23. PMID:22198458. |
four male patients with schizophrenia or schizoaffective disorder who had received at least 4 prior injections of the long-acting risperidone at a stable dose of 25 to 50 mg participated in this positron emission tomography study. |
2012-05-23 |
2023-08-12 |
human |